Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Boehringer Ingelheim International Gmbh

Bayer Healthcare Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Animal Health Gmbh

Bayer Pharma Aktiengesselschaft

Lars Bärfacker

Karl-Heinz Schlemmer

Adrian Tersteegen

Peter Kolkhof

Martin Hendrix

Heike Heckroth

Dagmar Karthaus

Volkhart Min-Jian Li

Andreas Knorr

Hans Briem

Marja Van Kampen

Frank-Thorsten Hafner

Franz-Josef Van Der Staay

Ulf Bömer

Joachim Schuhmacher

Ulrich Rosentreter

Rolf Grosser

Christina Erb

Mary F Fitzgerald

Gunter Karig

Klaus Münter

Leila Telan

Heike Gielen-Haertwig

Barbara Albrecht

Swen Allerheiligen

Johannes-Peter Stasch

Gerhard Siemeister

Hartmut Rehwinkel

William Johnston Scott

Jörg Keldenich

Roland Neuhaus

Ingo Flamme

Andrea Hägebarth

Frank Wunder

Alexander Hillisch

Raimund Kast

Jens Ackerstaff

Eva-Maria Becker

Hartmut Beck

Barbara Albrecht-Küpper

Wilhelm Bone

Simon Holton

Stuart Ince

Marion Hitchcock

Philip Lienau

Rudolf Schohe-Loop

Markus Follmann

Thomas Lampe

Nils Griebenow

Gorden Redlich

Kai Thede

Anne Mengel

Mario Jeske

Hanno Wild

Friederike Stoll

Ursula Mönning

Amaury Ernesto Fernandez-Montalvan

Jens-Kerim Ergüden

Elke Hartmann

Mark Meininghaus

Kersten Matthias Gericke

Ulrich Klar

Pierre Wasnaire

Alexandros Vakalopoulos

Hans-Georg Lerchen

Thomas Ernst Müller

Carsten Schmeck

Klemens Lustig

Katja Zimmermann

Knut Eis

Walter Hübsch

Joachim Kuhnke

Hanna Tinel

Christoph Gerdes

Benjamin Bader

Heinrich Meier

Stefan Heitmeier

Antje Margret Wengner

Anja Buchmüller

Niels Lindner

Arwed Cleve

Sven Ring

Joerg Keldenich

Yolanda Cancho Grande

Volker Schulze

Johannes Köbberling

Hartmut Schirok

Ulrich Ebert

Helmut Sonnenschein

Judith Günther

Joachim Telser

Mario Lobell

Haruka Shimizu

Stefan Weigand

Michael Härter

Olaf Panknin

Jürgen Klar

Keith Graham

Detlef Stöckigt

Heinz Graubaum

The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

Substituted S-alaninate derivatives

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

N-Methylbenzimidazoles as mIDH1 inhibitors

Compounds of formula (I) as defined herein and their use as pharmaceuticals. 

Benzyl substituted indazoles as BUB1 inhibitors

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted pyridobenzodiazepinone-derivatives and use thereof

Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

Heteroaryl substituted pyrazoles

The present invention relates to isothiazoles of general formula (I) which inhibit the mitotic checkpoint: in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Amino-substituted isothiazoles

The present invention relates to a method for the treatment of a cancer that is sensitive to Pi3K/Akt pathway inhibition by administering a therapeutically effective amount of a compound of formula (I) 

Imidazopyridazines as Akt kinase inhibitors

Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals. 

Substituted pyrazolopyrimidines as Akt kinase inhibitors

Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

Substituted imidazopyrazines as Akt kinase inhibitors

The present application relates to novel fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases

The application relates to imidazopyridazines of formula (I) which are useful as Akt inhibitors suitable for the treatment of cancer, and processes for their production and the use thereof.

The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Bicyclic aza heterocycles, and use thereof

The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use

Growing community of inventors

Oberhausen, Germany

Lars Bärfacker